An Open-Label Positron-Emission Tomography (PET) Study to Determine Brain Exposure of AZD1390 After Intravenous Administration of a Microdose [11C]AZD1390 to Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2017
At a glance
- Drugs AZD 1390 (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 20 Oct 2017 Planned End Date changed from 31 Jan 2018 to 30 Jan 2018.
- 20 Oct 2017 Planned primary completion date changed from 31 Jan 2018 to 30 Jan 2018.
- 20 Oct 2017 Status changed from not yet recruiting to recruiting.